studies indicate that the event rates for severe hy poglycemia range from 110 to 320 per 100 patient years for patients with type 1 diabetes and from 10 to 70 per 100 patient years for patients with type 2 diabetes. 6,7 Fatal episodes of hypoglycemia are presumably the outcome of ventricular cardiac arrhythmias, not brain death, perhaps mediated by sympathoadrenal activation and possible hy pokalemia, even though profound and prolonged hypoglycemia can be a cause of brain death. 8,9 Re gardless of the type of diabetes, the pathophysi ological mechanism of hypoglycemia, its associ ated risk factors, and interventions to reduce its occurrence must be understood by health care providers to minimize the risk of hypoglycemia. Therefore, in this article, we summarize the phys iology of hypoglycemia, as well as some major as pects of hypoglycemia related health consequenc es and possible ways to avoid them.
Introduction
Patients with diabetes treated with insulin must maintain euglycemia, which often takes years of delicate balancing between avoid ing hyperglycemia and hypoglycemia. It is hypo glycemia that seems to be the main barrier for obtaining optimal glycemic control in both type 1 and type 2 diabetes. [1] [2] [3] Good glycemic manage ment of diabetes prevents or delays microvascu lar complications and may reduce the risk of mac rovascular events.
2,3 For many years, a target he moglobin A 1c (HbA 1c ) of less than 7% has been rec ommended in most adult patients. Since 2013, the American Diabetes Association (ADA) rec ommendation for the treatment of diabetes pro posed patient centered glycemic goals, in which the general aim is to lower HbA 1c below 7% (as previously) but to compromise to HbA 1c below 8% when there is a high risk of hypoglycemia occur rence (ie, patients with a history of severe hypo glycemia, limited life expectancy, advanced micro and macrovascular complications) and strength en it to HbA 1c below 6.5% when it can be reached without significant hypoglycemia.
4,5
The incidence of hypoglycemia differs between studies, and that is why it is difficult to compare data due to different study designs, populations, and definitions of hypoglycemia used. Available
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Research Group, ~55% of severe hypoglycemic ep isodes occur during nocturnal sleep. 12 Nocturnal hypoglycemia is asymptomatic in most cases but such episodes can affect health and well being, and may be fatal. 13 Therefore, it is important to address strategies to prevent nocturnal hypogly cemia, including regular blood glucose measure ments at bedtime, consumption of appropriate bedtime snacks when necessary, implementation of certain insulin regimens and new technology that may limit the hypoglycemic episodes occur rence (eg, long acting insulin analogues, insu lin pumps with hypoglycemia blockade), among others. There are several risk factors for noctur nal hypoglycemia, such as daytime exercise, tight glycemic control, previous episodes of nocturnal hypoglycemia, and low bedtime glucose levels. [14] [15] [16] Glucose homeostasis and counterregulation In or der to develop therapies or methods aimed at lim iting the frequency of hypoglycemia, it is essen tial to know the homeostatic mechanisms of hy poglycemia detection and why they fail over time in both type 1 and type 2 diabetes. 17 Glucose ho meostasis, as described by Watts and Donovan, 18 is maintained through a classic sensory integrative pathway, where glucose variations are monitored carefully by glucose sensing cells in the periphery (hepatic portal and mesenteric vein) and some of the brain regions (especially in the hindbrain and hypothalamus). Glucose homeostasis is restored due to a direct connection to downstream inte grators that allow the glucose signal to be influ enced by inputs from brain regions (like circadian rhythms) before a motor output is generated by some of the effector mechanisms (eg, epinephrine or glucagon). Glucose sensing neurons are unique because they are able to use glucose as a signaling molecule that regulates its activity. The main step in the translation of the glucose signal seems to be glucokinase, AMP activated protein kinase, and the SUR 1 subtype of the ATP sensitive potassi um channel. Even though these neurons release neurotransmitters or neuropeptides, but not in sulin, they act similarly to pancreatic β cells (the classic glucose sensors), which indicates that they may share a similar mechanism for detecting fluc tuations in extracellular glucose concentrations.
18
When glucose level falls, the counterregulato ry response is triggered, which involves several physiological defense mechanisms. The first de fense mechanism in the hierarchy of counterreg ulation is a reduction of insulin secretion from β cells, and the second is an increase in the lev els of all counterregulatory hormones (gluca gon, adrenaline, cortisol, growth hormone) that can promote endogenous glucose production and restrict peripheral glucose usage. When there is a further decrease of a plasma glucose level, be havioral changes occur as a result of subjective awareness of hypoglycemia leading to carbohy drate consumption. 19 The glycemic threshold for a decrease in insulin is approximately 80 mg/dl. When the glucose concentration falls just below of clinical symptoms likely to be caused by a drop in plasma glucose level; 2) a low plasma glucose level at the time the symptoms occur; and 3) re lief of the symptoms when the blood glucose lev el restores to normal.
The symptoms of hypoglycemia cover activa tion of the autonomic central nervous system (au tonomic symptoms) and neuroglycopenic symp toms that are caused by reduced cerebral glucose absorption. Autonomic symptoms are the result of perception of physiological changes triggered by hypoglycemia, including tachycardia, palpita tions, shakiness, sweating, diaphoresis, anxiety, hunger, arability, pallor, and nausea. Neuroglyco penic symptoms include reduced concentration, blurred vision and dizziness, headache, weakness, fatigue, confusion, amnesia, focal neurologic def icits, seizures, and coma as a result of low glucose levels in the brain. 8 In 2005, the ADA agreed on how hypoglycemia should be defined and verified the guidelines in the year 2012. 10,11 According to the ADA, hypo glycemia is defined as an episode of an abnormal ly low plasma glucose concentration that leads to patient harm. It was agreed that there is no sin gle threshold value for plasma glucose concen tration that can define hypoglycemia. This is be cause the glycemic threshold for symptoms of hy poglycemia changes to lower plasma glucose con centrations after recent antecedent hypoglycemia and to higher plasma glucose concentrations in individuals with poorly controlled diabetes and few hypoglycemic events. However, according to the ADA an alert value for hypoglycemia should be recognized when plasma glucose level is equal to or falls below 70 mg/dl (3.9 mmol/l) because this is the level at which hormonal counterreg ulation is activated in patients without diabe tes, and it is the level that can cause a reduction of secretion of the counterregulatory hormones in response to a subsequent episode of hypogly cemia. Several types of hypoglycemic episodes have been classified, including asymptomatic and symptomatic hypoglycemia, and severe hypogly cemia. Asymptomatic hypoglycemia is recognized when the measured plasma glucose concentration is 70 mg/dl or lower without typical hypoglyce mic symptoms, and symptomatic hypoglycemia is recognized when typical symptoms occur. Hy poglycemia is defined as being mild or severe de pending on the ability to self treat. Self treated episodes are categorized as "mild". Severe hypo glycemia is defined as an event requiring assis tance of another individual and plasma glucose measurement may not be available but neurolog ical betterment due to the restoration of plasma glucose levels to normal is thought to be suffi cient enough to recognize an event.
1,10,11
It is also important to be aware of hypoglyce mic episodes that can occur at night, even though the episodes may not be detected by blood glu cose self measurement and often go unrecog nized. Based on information obtained by the Di abetes Control and Complication Trial (DCCT) known that hypoglycemia per se causes patho physiological changes resulting in suppression of counterregulatory hormonal and symptomat ic responses to another episode of hypoglycemia occurring 12 to 24 hours after the first episode.
30
The size of the suppression is related to the depth, duration, and frequency of previous hypoglyce mia episodes. 31 It is suggested that in type 1 dia betes, hypoglycemia unawareness occurs in 10% to 15% of patients and impaired awareness in 40% to 50%. 32 It should also be mentioned that hypo glycemia unawareness increases the risk of severe hypoglycemia by 6 fold for patients with type 1 diabetes and by 17 fold for those with type 2 di abetes.
33,34 Approximately 10% of patients with type 2 diabetes present impaired hypoglycemia awareness. 34 There is also a term, hypoglycemia associated autonomic failure (HAAF), which is a form of functional sympathoadrenal failure that increases the risk of severe hypoglycemia occur rence. This term describes the association be tween the 3 phenomena linked to disabling hypo glycemia, namely, defective hormonal counterreg ulation, altered counterregulatory hormone dis charge, and impaired hypoglycemia awareness. It is essential to differentiate HAAF from classic au tonomic neuropathy, in which HAAF is limited to the response to hypoglycemia, and autonomic ac tivities in other organs such as the heart, gastroin testinal tract, and bladder remain unaffected. 10,35 The sequence of events described above explains why striving for good glycemic control with in tensive insulin therapy leads to impaired symp tom awareness and counterregulatory defense against hypoglycemia and to higher incidence of severe hypoglycemia both among patients with type 1 and type 2 diabetes. 36,37 It has been proved that avoidance of hypoglycemia may lead to re versal of counterregulation, which demonstrates that it is an antecedent hypoglycemia that plays the key role in this phenomenon. 38
Hypoglycemia and the brain The brain is the organ that is most exposed to the adverse effects of hy poglycemia, as it is totally dependent on the con tinuous supply of glucose. The brain cannot syn thesize glucose, and reserves stored as glycogen are limited and sufficient only for a few minutes.
39
Different techniques of neuroimaging have been tested to better understand the way glucose is me tabolized in the brain.
40 It has been proved that recurrent hypoglycemia leads to brain adapta tions on many different levels.
40 These include changes in blood flow and transport of glucose to the brain, as well as administration of glucose within the brain, but also activation or deactiva tion of brain areas engaged in behavioral respons es.
40 Concern has been raised as to whether ex posure to recurrent severe hypoglycemia causes premature intellectual decline, and some contro versy has emerged around this subject.
The outcomes from a large cohort study per formed among older adults with type 2 diabetes suggest that a history of severe hypoglycemia is the physiological range, glucagon and epinephrine secretion is increased. Glucagon plays the leading role in increasing the glucose levels, while adrena line (in the presence of glucagon) plays a second ary role. In the case of a more severe decrease of glucose levels, there is an additional increase of cortisol, growth hormone, and other neurotrans mitter levels. At lower plasma glucose concentra tions, neurogenic and neuroglycopenic symp toms occur. The glycemic threshold for neurogen ic symptoms is ~55 mg/dl, and for disorders in mental function, it is ~46 mg/dl. 20,21 All 3 of these mechanisms are compromised in type 1 diabetes mellitus and advanced type 2 diabetes. 22 The eti ology of the defect remains to be elucidated; how ever, it has been suggested that the inability to secrete glucagon during hypoglycemia in type 1 diabetes is due to an intraislet defect, namely, failure in the local regulation of β to αcell sig naling by insulin, zinc, and probably the inhib itory neurotransmitter γ aminobutyric acid. 23 Besides the inability to secrete glucagon, there is also an impaired autonomic response to hypo glycemia, impaired awareness of hypoglycemia, and a reduction in catecholamine release occur rence. 17 The pathophysiology of glucose counter regulation is the same in type 1 and type 2 diabe tes, but it develops rapidly in type 1 diabetes and slowly in type 2 diabetes.
19
A few experimental studies have assessed the counterregulatory responses to nocturnal hypoglycemia. Results from an earlier study sug gested that sleep changes the glycemic threshold for the onset of the neuroendocrine counterreg ulatory response to lower glucose levels. 24 A later study by Banarer et al 25 concluded that patients with type 1 diabetes have reduced autonomic re sponses to hypoglycemia during sleep, most prob ably due to reduced sympathoadrenal responses, and thus, are less likely to be awakened by a hypo glycemic episode.
25 However, these studies exam ined hypoglycemia counterregulation solely dur ing the early nocturnal sleep, which differs mark edly from late sleep in sleep stage architecture. Therefore, Jauch Chara et al 26 assessed whether the counterregulatory response differs between sleep stages (early and late), and found that late nocturnal sleep reduces the extent of neuroen docrine counterregulation and may contribute to hypoglycemic episode accumulation in the latter part of the night.
Hypoglycemia unawareness The awareness of hy poglycemia and the same behavioral defense (hun ger) is mainly the result of perception of neuro genic symptoms, which are triggered through the activation of the autonomic nervous system by hypoglycemia.
27 Hypoglycemia is not only un pleasant and dangerous but, if persistent, may lead to the syndrome of hypoglycemia unaware ness: a condition where neuroglycopenia is pres ent before autonomic warning symptoms occur, or when a significant reduction in blood glucose level below normal is not sensed.
28,29 It is now clinical trials regarding type 2 diabetes: ACCORD, ADVANCE, and VADT. 53-55 A meta analysis of 4 large, randomized controlled trials (ACCORD, ADVANCE, VADT, and UKPDS), in which in tensive glycemic control was compared to stan dard glycemic control, revealed a modest reduc tion of major macrovascular events with inten sive glucose lowering treatment in the short to medium term; however, all cause and cardiovas cular mortality were not benefited. 56 Additionally, the ACCORD trial was prematurely interrupt ed because of excess mortality among inten sively treated patients. 53 A post hoc analysis of the ACCORD trial could not establish a relation ship between the higher mortality rate and tight glycemic control with certainty. 49 The current opinion is that the beneficial effect of strict gly cemic control on cardiovascular events is probably limited to patients without the presence of cardio vascular disease and less strict glycemic targets should be recommended for patients with a lon ger duration of diabetes, shorter life expectan cy, advanced macrovascular complications, and those prone to hypoglycemia. 5 Further analysis of the ACCORD study found a week inverse asso ciation between the annualized number of hypo glycemic episodes and risk of death. 57, 58 A recent systematic review and meta analysis, as well as cohort studies, have proved that severe hypoglycemia is associated with increased risk of cardiovascular disease and death among patients with type 2 diabetes. [59] [60] [61] [62] Regarding patients with type 1 diabetes, it is suggested that repeated hy poglycemia could be related to worse prognosis in terms of preclinical atherosclerosis, as well as considered an aggravating factor for it. [63] [64] [65] Only a few studies have examined whether hypoglyce mia may increase the risk of cardiovascular dis ease or death among patients with type 1 diabe tes, and the results were ambiguous. 64, [66] [67] [68] [69] Howev er, recently, a population based study of all cause mortality and cardiovascular disease in associa tion with prior history of hypoglycemia among patients with type 1 diabetes was performed.
70
This study found that cardiovascular disease in cidence is associated with severe hypoglycemic events that occurred in the preceding years, and that the risk of all cause mortality was associat ed with severe hypoglycemic events that occurred in the preceding 5 years. 70 The authors conclud ed that repeated severe hypoglycemic events can lead to higher risk of mortality and cardiovascu lar disease. 70 Furthermore, a study among Swed ish patients with type 1 diabetes found that those with prior severe hypoglycemic events present ed an increased risk of mortality after a cardio vascular event. 71 Unfortunately, the mechanism of hypoglyce miarelated all cause mortality and cardiovas cular events is not fully known; it is only sus pected that it is due to sympathetic adrenal ac tivations, prolonged cardiac repolarization, and increased cardiac arrhythmia risk. 72 Tsujimoto et al 73 showed that patients with type 1 and type linked to greater risk of dementia. 41 Similarly, in a recent 7 year follow up study among patients with type 2 diabetes, a significantly increased risk of dementia among patients with prior hypogly cemia was documented. 42 Furthermore, in a pro spective study among a diverse group of older pa tients (mean age, 74 years) with type 1 or type 2 diabetes initially free of dementia, a link between severe hypoglycemia and increased risk of demen tia was found.
43 An important observation coming from the study is that the authors found evidence for a bidirectional association between severe hy poglycemia and dementia, where reduced cogni tive function may increase the risk for hypoglyce mia, which can further compromise cognition.
43
On the other hand, there is also evidence com ing from the DCCT/Epidemiology of Diabetes In terventions and Complications (EDIC) trial that there is no relationship between long term decline in cognitive functioning over an 18 year period and relatively high rates of recurrent severe hy poglycemia episodes in a large group of patients with type 1 diabetes of short disease duration. 44 However, it must be noted that the study cohort consisted of relatively young patients with short duration of the disease, so the outcomes cannot be transformed directly to elderly patients and ones that become diabetic before the age of 5 years, as well as patients with impaired awareness of hypoglycemia. The high selectivity of the stud ied group limited the power of cognitive impair ment. 45 However, an association between hypo glycemia and impaired cognitive function in pa tients with type 1 diabetes has been shown in some studies, and there are also a few studies sug gesting that severe hypoglycemia in very young children is associated with mild impairments in cognitive function. 46-48 Taking this information together, it seems plausible that recurrent severe hypoglycemia may influence cognitive function of people with diabetes, but the groups of people at risk (age of diabetes onset, time of the disease duration, and rates and depths of hypoglycemic events) remain to be elucidated. 49
Hypoglycemia and the heart Diabetes elevates the risk of cardiovascular events to a similar lev el observed in people without diabetes, who have already suffered a myocardial infarction.
50 It is im portant to note that patients with type 1 diabe tes have a similar risk of developing premature cardiovascular disease to those with type 2 diabe tes when matched for age.
51 Hypoglycemia causes sympathoadrenal activation and counterregula tory hormone secretion, which in turn exert pro nounced cardiovascular effects with a potential to superimpose on coronary vascular walls that are already diseased and on dysfunctional cardi ac conductive systems, provoking serious cardio vascular events.
52
The potentially life threating effects of hy poglycemia on the cardiovascular system seem to have been overlooked for many years, until the announcement of the outcomes of 3 large required. 77, 78 Typically, in this type of disease, basal insulin alone is added as an initial insulin regimen. 79 This therapy covers insulin needed throughout the day and night and lowers blood glucose levels mainly due to suppression of inter prandial and night hepatic glucose production. Ei ther intermediate acting neutral protamine Hage dorn (NPH) or long acting insulin analogues may be used, but the latter are linked to less frequent overnight hypoglycemia and possibly slightly less weight gain. 80, 81 Eventually, due to the progressive character of the disease, some patients will need shorter acting insulin before meals. 82 In summary, the insulin treatment approach among patients with type 2 diabetes should be individualized to meet the special requirements of an individual pa tient, namely, dietary and exercise habits, domi nant glucose trends disclosed by self monitoring, and expected individual treatment goals. 75 In the newest report, an ADA workgroup rec ommends that, in order to restore recognition of hypoglycemia in patients with HAAF, rapid acting insulin analogues to decrease the risk of interprandial hypoglycemia and basal insulin an alogues to decrease the risk of nocturnal hypogly cemia should be used.
10 A meta analysis by Mon ami et al 83 indicates that long acting insulin ana logues are associated with a significant reduction in the rate of nocturnal hypoglycemia in type 1 di abetes. The cost of long acting analogues is higher compared with that of NPH insulin, but it must be remembered that the indirect cost of decreased hypoglycemia risk may be reduced, which is why it is the physician's responsibility to balance be tween costs and the clinical benefits that may be obtained. 83 Furthermore, a recent observational study showed that while the use of insulin ana logues versus human insulin may predispose to more frequent episodes of mild hypoglycemia, it does not increase the incidence of severe hypogly cemia in patients on intensive insulin therapy. 84 Recently, a newer ultra long acting insulin an alogue (ie, insulin degludec) has been developed, and, since September 2015, it has been approved by the US Food and Drug Administration for gly cemic control in adults with type 1 and type 2 diabetes.
85 This insulin demonstrates a differ ent pharmacokinetic/pharmacodynamic profile compared with insulin glargine and detemir and a longer duration of action (up to 42 hours with approximately 25 hour half life at steady state), which can lead to potential benefits. 86 As revealed in a recent review by Thuillier et al, 87 insulin de gludec shows good long term efficacy in provid ing glycemic control and reducing nocturnal hy poglycemia in patients with type 2 diabetes.
The role of education programs in hypoglycemia avoidance Beside insulin therapy itself, structured education programs that help people understand the ways in which they can manage their insulin therapy are important, as self management is es sential for successful diabetes treatment. An ex ample of a structured training program designed 2 diabetes who suffered from severe hypoglyce mia presented with critical problems, namely hy pothermia, hypokalemia, and abnormal QT pro longation. The authors emphasized that hypother mia was often observed and it can lead to arrhyth mias, such as ventricular tachycardia and atrial fibrillation, which were frequently observed. 73 It was also proved that patients with severe hypo glycemia presented with hypokalemia because hy pothermia, hyperinsulinemia, and increased lev el of catecholamines may cause potassium trans fer into the cell, while hypoglycemia and, in turn, hypokalemia increase the risk of lethal arrhyth mias. 73 In the above study, authors report that pa tients with both type 1 and type 2 diabetes who had severe hypoglycemia exhibited an abnormal QT prolongation and it can cause new onset atrial fibrillation; however, the causation in this study was not clear. 73 Similarly, Stahn et al 74 evaluated the risk of critical arrhythmias related to severe hypoglycemia in type 2 diabetes with cardiovas cular disease and found that severe episodes of hypoglycemia are associated with increased risk of severe ventricular arrhythmias.
Hypoglycemia avoidance Hypoglycemia can be prevented when patients at risk of severe hypo glycemia are identified, appropriate insulin reg imens and technical innovations (insulin ana logues, continuous glucose monitoring [CGM] , and insulin pumps, among others) are used, and patient education and empowerment is imple mented. From a practical point of view, it is im portant to be aware of factors for increased risk of hypoglycemia occurrence, namely insulin ex cess (ill timed and wrong type of insulin), de creased glucose intake (missed meals and over night fast), decreased endogenous glucose pro duction (after alcohol ingestion), increased glu cose utilization (during exercise), increased insu lin sensitivity (following exercise, in the middle of the night, and after weight loss), and decreased insulin clearance (as in renal failure). 1 Treatment goals and strategies should always be individual ized, as indicated in the newest ADA/European Association for the Study of Diabetes guidelines.
75
It has been proved that blunted autonomic symp toms and counterregulatory hormonal responses can be improved when even mild hypoglycemia episodes are avoided. 76 Restoration of autonomic symptoms of hypoglycemia can be obtained with in 2 weeks, and complete reversal of hypoglyce mia unawareness-within 3 months. 10
Optimal insulin therapies for hypoglycemia avoidance In patients with type 1 diabetes, the most adequate insulin therapy regimen that mimics normal physiology, adapts to the patient's life style, and reduces hypoglycemia risk is multiple daily insulin injection (MDII) therapy with insu lin analogues, or continuous subcutaneous insulin infusions (CSII) with the use of pump therapies.
5
In type 2 diabetes, β cell dysfunction progress es with time, and insulin therapy is frequently that RT CGM was more effective than SMBG in type 1 diabetes but retrospective CGM was not. 92 However, among patients with type 2 diabetes, retrospective CGM provided better glycemic control than SMBG. 92 Another study examined whether impaired awareness of hypoglycemia can be improved and severe hypoglycemia prevent ed with the use of CSII compared with MDII and RT CGM compared with SMBG among patients with type 1 diabetes.
93 Similar biomedical out comes were obtained with conventional MDI and SMBG regimens compared with CSII/RTCGM; however, satisfaction was higher with CSII. 93 Trang et al 94 performed a randomized trial to determine the incidence of severe and moder ate hypoglycemia with sensor augmented pump therapy with a low glucose suspension function compared with standard insulin pump therapy among patients with type 1 diabetes with im paired awareness of hypoglycemia. It was proved that the use of sensor augmented pump therapy with low glucose suspension reduced the rate of severe and moderate hypoglycemia in patients with type 1 diabetes and impaired hypoglycemia awareness over a 6 month period; however, no associated change in HbA 1c values was observed.
94
Another randomized, controlled, multi center, open label trial was performed in pa tients with type 1 diabetes and nocturnal hy poglycemia (the ASPIRE study,) who received sensor augmented insulin pump therapy with or without the threshold suspend feature for 3 months. 95 This study showed that the therapy with the threshold suspend feature reduced noc turnal hypoglycemia without increasing HbA 1c values. 95 The first step in developing an artificial pancreas is a quite recent advance in insulin treat ment technology, which is a sensor augmented insulin pump with automatic low glucose sus pension of the basal rate of the insulin for up to 2 hours once the interstitial glucose concentration reaches a preset threshold. This innovation is es pecially important for people who sleep through alarms, because it can potentially reduce severe hypoglycemic episodes at night. 96 Conclusions It is well known that good glycemic control prevents or delays microvascular compli cations and may reduce macrovascular events. Iat rogenic hypoglycemia is the major barrier for opti mal glycemic control because it is associated with morbidity and risk of death. In order to eliminate the risk of hypoglycemia in insulin treated pa tients, the treatment should be patient centered, which means that glycemic targets and insulin regimens, as well as any technical support used, should be individualized according to the patient's age, life expectancy, comorbidities, and preferenc es. It is currently not possible to maintain eug lycemia without hypoglycemia occurrence over the lifetime of most patients with diabetes melli tus, regardless of the type of disease. A great deal of hope is placed in technical investigations that might help manage this situation.
to maintain glucose control while enabling di etary freedom among type 1 diabetes patients was a multicenter randomized controlled study, DAFNE. 88 It has been carried out in the United Kingdom and resulted in improved HbA 1c levels and quality of life with no significant increase in severe hypoglycemia incidence. 88 A similar educa tion and training program for intensified insulin therapy on type 1 diabetes has been run in Düssel dorf and was linked to a reduction of HbA 1c value from 8.1% to 7.3% and a decrease of severe hy poglycemia occurrence from 0.37 to 0.14 events per patient per year. 89 In 2016, outcomes of a pragmatic, cluster randomized controlled trial of the CASCADE intervention that assessed efficacy of a clinic based structured educational group incorporating psychological approaches to improve long term glycemic control, quality of life, and psychologi cal functioning in children and adolescents with type 1 diabetes was published. 90 The results indi cated that delivering such educational programs remains challenging and that standardized train ing failed to demonstrate improvement in HbA 1c values among patients with poor diabetic con trol. 90 One of the reasons for that is a high rate of lack of response to invitations and failure to attend meetings among young people and their families. 90 Therefore, although the benefits of ed ucation are clear, determining the optimal edu cational program to provide insulin treated pa tients with the correct information on how to manage diabetes well requires further investiga tion. All patients with diabetes should obtain pre cise information on how to recognize and treat hypoglycemia and should know how to prevent it. Physicians should always ask patients about hypoglycemia incidence and talk over strategies for its management.
New technology in hypoglycemia avoidance Tech nical innovations in insulin delivery and glucose monitoring are becoming increasingly impor tant in the improvement of glycemic control with avoidance of hypoglycemia episodes, especially the development of new CSII and CGM systems, including real time continuous glucose moni toring (RT CGM) or "closed loop" systems. Self monitoring of blood glucose (SMBG) is a critical part of insulin therapy. However, several factors limit adherence to SMBG (namely, pain, motiva tion, and cost), which is why RT CGM systems have been developed. RT CGM allows patients to observe the direction and rate of change of plasma glucose in real time via an electrode in serted into the interstitial fluids of subcutane ous tissue, and it was proved that this technical support leads to an improvement of HbA 1c levels without increased risk of hypoglycemia in adults on intensified insulin therapy.
91
A systematic review and meta analysis per formed by Poolsu et al 92 analyzed effectiveness of CGM and RT CGM on glucose control among pa tients with type 1 and type 2 diabetes, and found
